Feel free to follow my blog for future posts :)
It has been perceived that the U.S relatively spends more in medical care with uncertain patient outcomes matched against it. The health sector will cover one-fifth of the U.S domestic product by 2020. Hence something has to be done to break this cycle of high and flat results.
An increasing number of U.S tech companies like Amazon, Apple, Google and others, some in partnership with other major U.S. non-health companies, take this challenge as an opportunity to make necessary innovations to change our approach to human medicine.
Advances in genomics like falling costs of gene sequencing due to improved processing, data storage, and sensors, and in gene editing the development of CRISPR-Cas9 has created ways to alter the human genetic code and cure diseases.
Moreover, it has led to the rapid improvement of personalized medicine for patient’s DNA custom treatment alongside precision treatment that offers optimal treatment to an individual. Faster diagnostic tests such as liquid biopsy will bring significant reductions in treatment.
There is an emergence of digital medical technology due to the presence of new technologies such as virtual and augmented reality, artificial intelligence, robotics and 3D printing, transform provider capabilities. Electronic health records and data sources are generating new troves of data.
The advancement of health technology can accelerate machine learning that will improve the number of diagnostic insights and predictive approaches to managing health such as addressing, diagnosing and treating 80 percent of the cancers in the world.
Consequently, all these technological encroachments will have a potential to reduce the cost of care and benefit patients. However, there is existing economic inequality and disparity in U.S. health care outcomes; for instance, health care spending has increased among the wealthy while decreased among the poor making the riches live longer than the poor according to the statistics.
Currently, the costs are still high, and this brings a concern to whether these technology reimbursements will be available to all or only to those who can afford.
A series of questions have aroused about what happens when the humanity has complete control on its own evolution and how we can handle the risks that accompany it. It is critical for both public and private sector leaders to address complex challenges on the health policy priority in the U.S
Feel free to follow my blog for future posts :) #Support